fda warning letters compounded semaglutide tirzepatide 2025 and Novo Nordisk Warn of GLP-1 Telehealth Compounding Take Down – What's Next? FDA Sends Warning Letters to
Description
Peptide synthesis and excipient sourcing are under strain upstream, while downstream logistics providers invest in temperature-controlled transport and real-time tracking to maintain product integrity
Weight Loss Results Mean weight loss reached 12.2% with 3.6 mg and 13.0% with 6.0 mg versus 5.4% with placebo
Longland TM, Oikawa SY, Mitchell CJ, Devries MC, Phillips SM
The trial is expected to finish in 2028
